Findings

What do systematic reviews say?

1,923 questions · 1,956 findings · 143 reviews · Musculoskeletal

Sort:Best matchNewestHighest certainty Download CSV

No studies found 555 · 28.4%GRADE not reported 107 · 5.5%Very low 255 · 13%Low 555 · 28.4%Moderate 357 · 18.3%High 127 · 6.5%

Kinesiotaping vs other conservative treatment

Quality of life · rotator cuff disease

1 finding from 1 review

Kinesio taping for rotator cuff disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Kinesiotaping vs other conservative treatment

Global assessment of treatment success · rotator cuff disease

The review found no eligible studies for this question.

1 finding from 1 review

Kinesio taping for rotator cuff disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Kinesiotaping vs other conservative treatment

Adverse events№ of participants: 391 (7 RCTs) · rotator cuff disease

1 finding from 1 review

Kinesio taping for rotator cuff disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Kinesiotaping vs sham taping

Function · rotator cuff disease

1 finding from 1 review

Kinesio taping for rotator cuff disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Kinesiotaping vs sham taping

Pain on motion · rotator cuff disease

1 finding from 1 review

Kinesio taping for rotator cuff disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Kinesiotaping vs sham taping

Active range of motion (shoulder abduction) without pain. Scale: 0 to 180 degrees№ of participants: 143(3 RCTs) · rotator cuff disease

1 finding from 1 review

Kinesio taping for rotator cuff disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Kinesiotaping vs sham taping

Global assessment of treatment success · rotator cuff disease

The review found no eligible studies for this question.

1 finding from 1 review

Kinesio taping for rotator cuff disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Kinesiotaping vs sham taping

Quality of life№ of participants: (0 studies) · rotator cuff disease

The review found no eligible studies for this question.

1 finding from 1 review

Kinesio taping for rotator cuff disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Kinesiotaping vs sham taping

Adverse events№ of participants: 136 (4 RCTs) · rotator cuff disease

1 finding from 1 review

Kinesio taping for rotator cuff disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Kinesiotaping vs other conservative treatment

Overall pain · rotator cuff disease

1 finding from 1 review

Kinesio taping for rotator cuff disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

Kinesiotaping vs other conservative treatment

Function · rotator cuff disease

1 finding from 1 review

Kinesio taping for rotator cuff disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Very low

NSAID injection vs glucocorticoid injection

Resolution at 12 to 24 weeks Quinell Grade (range 0 to 4, resolved disease is grade 0) · adults (> 18 years of age) with trigger finger

NSAID injection showed no clear difference in resolution at 12 to 24 weeks Quinell Grade (range 0 to 4, resolved… compared with glucocorticoid injection (low certainty).

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs (NSAIDs) for trigger finger 2021 · Cochrane Headline outcomes only
RR 0.83 [0.62, 1.11]
2 studies · 231 participants
Low

NSAID injection vs glucocorticoid injection

Persistent moderate to severe symptoms at 12 to 24 weeks · adults (> 18 years of age) with trigger finger

NSAID injection may leads to higher persistent moderate to severe symptoms at 12 to 24 weeks compared with glucocorticoid injection (low certainty).

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs (NSAIDs) for trigger finger 2021 · Cochrane Headline outcomes only
RR 2.03 [1.19, 3.46]
2 studies · 231 participants
Low

NSAID injection vs glucocorticoid injection

Recurrence · adults (> 18 years of age) with trigger finger

It is very uncertain whether NSAID injection changes recurrence at 12 to 24 weeks compared with glucocorticoid injection (very low certainty).

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs (NSAIDs) for trigger finger 2021 · Cochrane Headline outcomes only
RR 0.07 [0.01, 0.38]
2 studies · 231 participants
Very low

NSAID injection vs glucocorticoid injection

Total active motion · adults (> 18 years of age) with trigger finger

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs (NSAIDs) for trigger finger 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 99 participants
Low

NSAID injection vs glucocorticoid injection

Post-operative pain (residual pain, any severity) · adults (> 18 years of age) with trigger finger

NSAID injection showed no clear difference in residual pain compared with glucocorticoid injection (low certainty).

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs (NSAIDs) for trigger finger 2021 · Cochrane Headline outcomes only
RR 0.84 [0.54, 1.31]
2 studies · 231 participants
Low

NSAID injection vs glucocorticoid injection

Global assessment of treatment success · adults (> 18 years of age) with trigger finger

NSAID injection showed no clear difference in participant‐reported treatment success compared with glucocorticoid injection (low certainty).

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs (NSAIDs) for trigger finger 2021 · Cochrane Headline outcomes only
RR 0.95 [0.74, 1.23]
1 study · 121 participants
Low

NSAID injection vs glucocorticoid injection

Adverse events · adults (> 18 years of age) with trigger finger

It is very uncertain whether NSAID injection changes adverse events compared with glucocorticoid injection (very low certainty).

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs (NSAIDs) for trigger finger 2021 · Cochrane Headline outcomes only
RR 2
2 studies · 231 participants
Very low

Anti‐IL‐5 mAb (mepolizumab) vs placebo

All‐cause mortality · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis

Mepolizumab showed no clear difference in mortality compared with placebo (low certainty).

1 finding from 1 review

Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes only
Peto OR 7.39 [0.15, 372.38]
Studies not reported
Low

Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care

Remission · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…

Active drug (etanercept or belimumab) with standard therapy showed no clear difference in remission (number of patients with remission) compared with standard therapy with placebo (low certainty).

1 finding from 1 review

Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes only
RR 0.97 [0.89, 1.07]
Studies not reported
Low